Rizzo Alessandro, Ricci Angela Dalia, Brandi Giovanni
Struttura Semplice Dipartimentale di Oncologia Medica per la Presa in Carico Globale del Paziente Oncologico "Don Tonino Bello", I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Viale Orazio Flacco 65, 70124 Bari, Italy.
Medical Oncology Unit, National Institute of Gastroenterology, "Saverio de Bellis" Research Hospital, 70013 Castellana Grotte, Italy.
J Pers Med. 2022 Oct 29;12(11):1788. doi: 10.3390/jpm12111788.
Recent years have seen the advent of novel treatment options for hepatocellular carcinoma (HCC). Given a strong biological rationale supporting this strategy, multiple studies have explored the role of combination treatments including locoregional plus systemic therapies to produce a synergistic effect and enhance antitumor activity. Among locoregional therapies, several clinical trials assessing trans-arterial chemoembolization (TACE) have been recently presented and published. In the current paper, we discuss available evidence and current and future research on combined TACE and systemic treatments, including antiangiogenic agents, immune checkpoint inhibitors, and immune-based combinations for HCC patients.
近年来，肝细胞癌（HCC）出现了新的治疗选择。鉴于有强有力的生物学理论支持这一策略，多项研究探讨了联合治疗的作用，包括局部区域治疗与全身治疗相结合，以产生协同效应并增强抗肿瘤活性。在局部区域治疗中，最近已经公布并发表了几项评估经动脉化疗栓塞术（TACE）的临床试验。在本文中，我们讨论了关于TACE与全身治疗联合应用的现有证据以及当前和未来的研究，这些全身治疗包括抗血管生成药物、免疫检查点抑制剂以及针对HCC患者的基于免疫的联合治疗。
